Follow
David Matheson
David Matheson
Verified email at wlv.ac.uk
Title
Cited by
Cited by
Year
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage …
ND James, MR Sydes, NW Clarke, MD Mason, DP Dearnaley, MR Spears, ...
The Lancet 387 (10024), 1163-1177, 2016
20832016
Abiraterone for prostate cancer not previously treated with hormone therapy
ND James, JS de Bono, MR Spears, NW Clarke, MD Mason, ...
New England Journal of Medicine 377 (4), 338-351, 2017
17512017
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
CC Parker, ND James, CD Brawley, NW Clarke, AP Hoyle, A Ali, ...
The Lancet 392 (10162), 2353-2366, 2018
10822018
Addition of docetaxel to hormonal therapy in low-and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
NW Clarke, A Ali, FC Ingleby, A Hoyle, CL Amos, G Attard, CD Brawley, ...
Annals of Oncology 30 (12), 1992-2003, 2019
3652019
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol
MR Sydes, MR Spears, MD Mason, NW Clarke, DP Dearnaley, ...
Annals of Oncology 29 (5), 1235-1248, 2018
2712018
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised …
G Attard, L Murphy, NW Clarke, W Cross, RJ Jones, CC Parker, ...
The lancet 399 (10323), 447-460, 2022
2322022
STAMPEDE investigators. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive …
ND James, MR Sydes, NW Clarke, MD Mason, DP Dearnaley, MR Spears, ...
Lancet 387 (10024), 1163-1177, 2016
2152016
Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE trial
ND James, MR Spears, NW Clarke, DP Dearnaley, MD Mason, CC Parker, ...
JAMA oncology 2 (3), 348-357, 2016
2032016
Abiraterone in “high-” and “low-risk” metastatic hormone-sensitive prostate cancer
AP Hoyle, A Ali, ND James, A Cook, CC Parker, JS De Bono, G Attard, ...
European urology 76 (6), 719-728, 2019
1832019
An introduction to the study of education
D Matheson
Routledge, 2014
141*2014
Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators. Radiotherapy to the primary tumour for newly diagnosed …
CC Parker, ND James, CD Brawley, NW Clarke, AP Hoyle, A Ali, ...
Lancet 392 (10162), 2353-2366, 2018
1232018
How well prepared are medical students for their first year as doctors? The views of consultants and specialist registrars in two teaching hospitals
C Matheson, D Matheson
Postgraduate Medical Journal 85 (1009), 582-589, 2009
1192009
Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial
G Attard, MR Sydes, MD Mason, NW Clarke, D Aebersold, JS de Bono, ...
European urology, 2014
782014
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab
S Lin, NA Kennedy, A Saifuddin, DM Sandoval, CJ Reynolds, RC Seoane, ...
Nature communications 13 (1), 1379, 2022
712022
Lifelong learning and lifelong education: A critique
D Matheson, C Matheson
Research in Post‐Compulsory Education 1 (2), 219-236, 1996
701996
Adding celecoxib with or without zoledronic acid for hormone-naďve prostate cancer: long-term survival results from an adaptive, multiarm, multistage, platform, randomized …
MD Mason, NW Clarke, ND James, DP Dearnaley, MR Spears, ...
Journal of clinical oncology 35 (14), 1530, 2017
642017
Management of patients with advanced prostate cancer. Part I: intermediate-/high-risk and locally advanced disease, biochemical relapse, and side effects of hormonal treatment …
S Gillessen, A Bossi, ID Davis, J de Bono, K Fizazi, ND James, N Mottet, ...
European urology 83 (3), 267-293, 2023
582023
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial
CC Parker, ND James, CD Brawley, NW Clarke, A Ali, CL Amos, G Attard, ...
PLoS medicine 19 (6), e1003998, 2022
522022
Quality of life in men with prostate cancer randomly allocated to receive docetaxel or abiraterone in the STAMPEDE trial
HL Rush, L Murphy, AK Morgans, NW Clarke, AD Cook, G Attard, ...
Journal of clinical oncology: official journal of the American Society of …, 2022
522022
Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC …
S Gillessen, A Bossi, ID Davis, J de Bono, K Fizazi, ND James, N Mottet, ...
European Journal of Cancer 185, 178-215, 2023
492023
The system can't perform the operation now. Try again later.
Articles 1–20